tiprankstipranks
Trending News
More News >

CLINUVEL CEO Takes Temporary Leave; Operations to Continue Uninterrupted

Story Highlights
CLINUVEL CEO Takes Temporary Leave; Operations to Continue Uninterrupted

The latest update is out from Clinuvel Pharmaceuticals Limited ( (AU:CUV) ).

CLINUVEL Pharmaceuticals announced that CEO Dr. Philippe Wolgen will temporarily step down from his full duties to address an acute medical condition, with COO Lachlan Hay stepping in as Acting CEO. The company assures stakeholders that operations will continue smoothly during Dr. Wolgen’s absence, reflecting confidence in the executive team’s ability to maintain business continuity and achieve the company’s objectives.

More about Clinuvel Pharmaceuticals Limited

CLINUVEL Pharmaceuticals Limited is a global specialty pharmaceutical group headquartered in Melbourne, Australia. The company focuses on developing and commercializing treatments for genetic, metabolic, systemic, and life-threatening acute disorders, with a particular emphasis on photomedicine and melanocortin peptides. CLINUVEL’s lead therapy, SCENESSE®, is approved for use in several countries as a systemic photoprotective drug for patients with erythropoietic protoporphyria (EPP).

YTD Price Performance: -5.56%

Average Trading Volume: 479

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $365.5M

Learn more about CUV stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App